Hubei Hongyuan Pharmaceutical Technology バランスシートの健全性
財務の健全性 基準チェック /56
Hubei Hongyuan Pharmaceutical Technology has a total shareholder equity of CN¥4.3B and total debt of CN¥362.4M, which brings its debt-to-equity ratio to 8.3%. Its total assets and total liabilities are CN¥5.9B and CN¥1.5B respectively. Hubei Hongyuan Pharmaceutical Technology's EBIT is CN¥132.4K making its interest coverage ratio -0. It has cash and short-term investments of CN¥1.7B.
主要情報
8.3%
負債資本比率
CN¥362.39m
負債
| インタレスト・カバレッジ・レシオ | -0.006x |
| 現金 | CN¥1.69b |
| エクイティ | CN¥4.35b |
| 負債合計 | CN¥1.51b |
| 総資産 | CN¥5.86b |
財務の健全性に関する最新情報
更新なし
Recent updates
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%
Oct 08
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable
Aug 23Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear
Apr 29Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely
Mar 14財務状況分析
短期負債: 301246's short term assets (CN¥3.0B) exceed its short term liabilities (CN¥1.2B).
長期負債: 301246's short term assets (CN¥3.0B) exceed its long term liabilities (CN¥331.3M).
デット・ツー・エクイティの歴史と分析
負債レベル: 301246 has more cash than its total debt.
負債の削減: 301246's debt to equity ratio has reduced from 25.9% to 8.3% over the past 5 years.
債務返済能力: 301246's operating cash flow is negative, therefore debt is not well covered.
インタレストカバレッジ: 301246 earns more interest than it pays, so coverage of interest payments is not a concern.